#1 Clinical Trials Search in Europe

Remestemcel

Remestemcel-L, an innovative stem cell therapy, is being investigated in various clinical trials for its potential to treat a range of medical conditions. This article explores the use of Remestemcel-L in clinical studies, focusing on its application in treating inflammatory bowel diseases, graft-versus-host disease, and other conditions. We’ll examine the safety, efficacy, and potential benefits of this cutting-edge treatment.

Table of Contents

What is REMESTEMCEL?

REMESTEMCEL, also known as Prochymal or remestemcel-L, is an innovative medical treatment that uses mesenchymal stem cells (MSCs) derived from adult human bone marrow[1]. These special cells have the ability to develop into different types of cells in the body and possess unique properties that can help reduce inflammation and promote tissue repair[2].

How does REMESTEMCEL work?

REMESTEMCEL works by harnessing the natural healing properties of mesenchymal stem cells. When introduced into the body, these cells can:

  • Interact with the immune system to reduce inflammation
  • Help repair damaged tissues
  • Promote the growth of new blood vessels
  • Release substances that support the healing process

This unique combination of effects makes REMESTEMCEL a promising treatment for various inflammatory and autoimmune conditions[3].

What conditions is REMESTEMCEL being studied for?

REMESTEMCEL is currently being investigated for several medical conditions, including:

  1. Graft-versus-host disease (GVHD): A serious complication that can occur after bone marrow transplantation[1].
  2. Crohn’s disease: A type of inflammatory bowel disease that affects the digestive tract[4].
  3. Ulcerative colitis: Another form of inflammatory bowel disease that primarily affects the colon and rectum[5].
  4. Acute respiratory distress syndrome (ARDS): A severe lung condition that can be caused by COVID-19 and other infections[2].
  5. Type 1 diabetes: An autoimmune condition where the body attacks insulin-producing cells in the pancreas[6].
  6. Heart attack (acute myocardial infarction): A condition where blood flow to the heart is blocked, causing damage to heart muscle[7].

How is REMESTEMCEL administered?

REMESTEMCEL is typically given as an intravenous (IV) infusion. The exact dosage and frequency of treatments can vary depending on the condition being treated and the specific clinical trial protocol. For example:

  • In studies for GVHD, patients may receive infusions twice a week for four consecutive weeks[8].
  • For Crohn’s disease and ulcerative colitis, treatments might involve multiple infusions over several weeks[4].
  • In trials for heart attack patients, a single infusion may be given shortly after the cardiac event[7].

Current Clinical Trials

REMESTEMCEL is being studied in several clinical trials for different conditions. Some notable ongoing studies include:

  • A phase IB/IIA study for treatment-resistant Crohn’s colitis[4]
  • A phase IB/IIA study for medically refractory ulcerative colitis[5]
  • A study for pediatric patients with acute GVHD who have failed steroid treatment[1]
  • An expanded access program for ARDS due to COVID-19 infection[2]

Safety and Side Effects

Based on current clinical trials, REMESTEMCEL appears to have a good safety profile. However, as with any medical treatment, there may be potential risks and side effects. Common side effects reported in studies include[3]:

  • Infusion-related reactions
  • Headache
  • Nausea
  • Fever

It’s important to note that the long-term effects of REMESTEMCEL are still being studied, and patients should discuss potential risks with their healthcare providers.

Future Potential

REMESTEMCEL represents an exciting area of medical research with potential applications in various inflammatory and autoimmune conditions. As more clinical trials are completed, we may gain a better understanding of its effectiveness and optimal use in different patient populations.

While REMESTEMCEL shows promise, it’s important to remember that it is still an investigational treatment. Patients interested in this therapy should consult with their doctors about the possibility of participating in clinical trials or accessing the treatment through expanded access programs where available.

Aspect Details
Product Name Remestemcel-L (also known as PROCHYMAL®)
Type of Treatment Ex-vivo cultured adult human mesenchymal stem cell product
Source Allogeneic bone marrow-derived mesenchymal stem cells
Administration Method Intravenous infusion
Conditions Studied Crohn’s disease, ulcerative colitis, acute graft-versus-host disease, acute respiratory distress syndrome due to COVID-19, type 1 diabetes mellitus
Potential Benefits Reduction of inflammation, tissue repair, immunomodulation
Clinical Trial Phases Phase I, II, and expanded access programs
Primary Outcomes Safety assessment, treatment-related adverse events, clinical response rates
Secondary Outcomes Quality of life measures, disease-specific indicators, survival rates

FAQ

  • What is Remestemcel-L? Remestemcel-L is an ex-vivo cultured adult human mesenchymal stem cell product. It's derived from bone marrow and is being studied for its potential to treat various inflammatory and immune-related conditions.
  • What conditions is Remestemcel-L being tested for in clinical trials? Remestemcel-L is being studied for several conditions, including Crohn's disease, ulcerative colitis, acute graft-versus-host disease (aGVHD), acute respiratory distress syndrome (ARDS) due to COVID-19, and type 1 diabetes mellitus.
  • How is Remestemcel-L administered in clinical trials? In most trials, Remestemcel-L is administered through intravenous infusion. The dosage and frequency of administration vary depending on the condition being treated and the specific trial protocol.
  • What are the potential benefits of Remestemcel-L? Remestemcel-L has shown potential in reducing inflammation, promoting tissue repair, and modulating the immune system. In clinical trials, it's being evaluated for its ability to improve symptoms, induce remission, and enhance overall quality of life in patients with various conditions.
  • Are there any known side effects of Remestemcel-L? While the safety profile of Remestemcel-L is still being studied, clinical trials are closely monitoring for any adverse events. The primary outcomes of many trials include assessing treatment-related adverse events to ensure patient safety.

Ongoing Clinical Trials on Remestemcel

  • Study on Autologous Chondrocytes and Remestemcel for Knee Cartilage Lesions in Patients with Symptomatic Articular Cartilage Damage

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Remestemcel-L: An ex-vivo cultured adult human mesenchymal stem cell product derived from bone marrow, being studied for its potential therapeutic effects in various inflammatory and immune-related conditions.
  • Mesenchymal Stem Cells (MSCs): Adult stem cells that can differentiate into various cell types and have immunomodulatory properties, potentially helping to reduce inflammation and promote tissue repair.
  • Graft-Versus-Host Disease (GVHD): A condition that can occur after a bone marrow or stem cell transplant, where the donor cells attack the recipient's body, causing inflammation and damage to various organs.
  • Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
  • Ulcerative Colitis: A chronic inflammatory bowel disease that affects the innermost lining of the large intestine (colon) and rectum, causing inflammation and ulcers.
  • Acute Respiratory Distress Syndrome (ARDS): A serious lung condition that causes fluid to build up in the air sacs, leading to severe breathing difficulties and low blood oxygen levels.
  • Type 1 Diabetes Mellitus: An autoimmune disorder in which the body's immune system attacks and destroys insulin-producing beta cells in the pancreas, leading to high blood sugar levels.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, evaluating the safety and efficacy of new treatments, drugs, or devices.
  • Intravenous Infusion: A method of delivering medications or fluids directly into a vein using a needle or catheter.
  • Immunomodulatory: Capable of modifying or regulating immune responses in the body, either by enhancing or suppressing the immune system.

References

  1. https://clinicaltrials.gov/study/NCT02336230
  2. https://clinicaltrials.gov/study/NCT04366830
  3. https://clinicaltrials.gov/study/NCT00284986
  4. https://clinicaltrials.gov/study/NCT04548583
  5. https://clinicaltrials.gov/study/NCT04543994
  6. https://clinicaltrials.gov/study/NCT00690066
  7. https://clinicaltrials.gov/study/NCT00877903
  8. https://clinicaltrials.gov/study/NCT00826046